AbsoluteIDQ® p180 by BIOCRATES Life Sciences AG: Cutting-edge Test kit Made in Austria Helps Develop the World's First Metabolomics-based Blood Test to Predict Alzheimer's Disease

• A US research team has developed the world's first blood test capable of predicting, with 90% accuracy, the risk of Alzheimer's disease 2-3 years in advance. The findings, published in Nature Medicine, were generated using the AbsoluteIDQ^® p180 test kit by Austrian BIOCRATES Life Sciences AG.

INNSBRUCK, Austria, March 21, 2014 /CNW/ - A team of US researchers has developed the world's first blood test capable of predicting Alzheimer's. The first-of-its-kind study, recently published in Nature  Medicine, used the AbsoluteIDQ® p180 test kit by BIOCRATES Life Sciences AG, a leading Austrian biotech company specialized in targeted metabolomics.

A cure for Alzheimer's disease is currently not available, but early detection could contribute to substantially improving the situation of affected individuals. While biomarkers have long been expected to provide important clues to the causes of Alzheimer's, current biomarkers are either invasive, time-consuming, or costly. The team now discovered that a set of 10 lipids from peripheral blood predicts the development of Alzheimer's with 90% accuracy and years in advance. Although it will take some time to develop a test fit for routine use, these findings are an impressive example of the power of metabolomics in diagnosis and biomarker discovery.

AbsoluteIDQ p180 provides extensive metabolic information from a single targeted assay, quantifying 186 analytes. It uses minute sample volumes (10 µL) and is suitable for use with a wide range of biological samples, making it an excellent choice for researchers looking for a cost-effective solution to measure endogenous metabolites under quality-controlled conditions.

About  BIOCRATES 

BIOCRATES Life Sciences AG offers unique solutions for targeted, quantitative and quality controlled metabolic phenotyping ('deep phenotyping'). The company's mass spectrometry based assays are marked by unprecedented accuracy and precision, providing a comprehensive understanding of phenotypes and metabolic pathways. BIOCRATES metabolomics solutions set new standards that can readily meet the rigorous demands of modern research.

For more information, please go to http://www.biocrates.com.

SOURCE: Biocrates Life Sciences AG

Martina Klocker, [email protected], Phone: [phone]